What is the incidence of febrile neutropenia in patients treated with pembrolizumab (Keytruda) monotherapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Febrile Neutropenia with Pembrolizumab Monotherapy is Extremely Rare

Pembrolizumab monotherapy carries a very low risk of febrile neutropenia, with rates of 0% reported in major clinical trials. This stands in stark contrast to pembrolizumab combined with chemotherapy, where febrile neutropenia becomes a significant concern.

Incidence Based on Treatment Regimen

Pembrolizumab Monotherapy

The risk of febrile neutropenia with pembrolizumab alone is negligible. In the KEYNOTE-119 trial of pembrolizumab monotherapy for metastatic triple-negative breast cancer, neutropenia of any grade occurred in 0% of patients 1. Similarly, in KEYNOTE-012 for head and neck cancer, serious adverse reactions occurred in 45% of patients, but febrile neutropenia was not among the commonly reported events 2.

Pembrolizumab Plus Chemotherapy

When pembrolizumab is combined with chemotherapy, febrile neutropenia becomes clinically relevant:

  • KEYNOTE-355 (pembrolizumab + chemotherapy for triple-negative breast cancer): Grade 3-4 neutropenia occurred in 30% of patients in both the pembrolizumab-chemotherapy and placebo-chemotherapy arms, indicating the neutropenia risk is driven by chemotherapy rather than pembrolizumab 1

  • KEYNOTE-522 (neoadjuvant/adjuvant setting for early-stage TNBC): Febrile neutropenia was a serious adverse reaction in 15% of patients, and was the most common reason for treatment interruption (2.8%) 2

  • KEYNOTE-048 (pembrolizumab + platinum/5-FU for head and neck cancer): Febrile neutropenia occurred in 2.9% of patients receiving the combination, compared to minimal rates with pembrolizumab monotherapy 2

Clinical Context and Mechanism

The mechanism of neutropenia differs fundamentally between monotherapy and combination therapy:

  • Chemotherapy-induced neutropenia is predictable, dose-dependent, and occurs early (typically 7-14 days post-administration)
  • Immune-mediated neutropenia from pembrolizumab alone is exceedingly rare but can occur at any time, even after 36 cycles of therapy 3

Recent pharmacovigilance data from FAERS identified 856 serious neutropenia cases among 14,747 pembrolizumab-related adverse events, with 86.5% (269/311) of febrile neutropenia cases occurring in patients receiving concomitant chemotherapy 4. The median time-to-onset was 14.5 days with chemotherapy versus 39 days without chemotherapy 4.

Key Clinical Implications

For pembrolizumab monotherapy:

  • Routine G-CSF prophylaxis is not indicated
  • Standard neutropenic precautions are unnecessary
  • If neutropenia develops, consider immune-mediated etiology and perform bone marrow biopsy to exclude alternative causes 3

For pembrolizumab plus chemotherapy:

  • Follow standard chemotherapy-related febrile neutropenia protocols
  • Risk stratification using MASCC score (≥21 indicates low risk suitable for outpatient management) remains valid 5
  • Consider G-CSF support based on chemotherapy regimen risk, not pembrolizumab
  • If neutropenia persists beyond expected chemotherapy nadir (>10 days), consider immune-mediated component 5

Important Caveats

While rare, immune-mediated neutropenia from pembrolizumab can be severe and life-threatening when it occurs 6. One case report described grade 3 pancytopenia as part of multiorgan immune toxicity requiring high-dose methylprednisolone 6. The mortality rate in reported neutropenia cases was 19.4%, though this includes combination therapy cases 4.

Bottom line: Pembrolizumab monotherapy poses essentially no risk of febrile neutropenia. The risk emerges only when combined with myelosuppressive chemotherapy, where the chemotherapy—not the immunotherapy—drives the neutropenia risk.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.